

## Supplementary Material

**Article Title:** Efficacy and Tolerability of Ultra–Low-Dose Mirtazapine in Adult Chronic Insomnia

**Author(s):** Rony Berbara, MD; Kamal Gandotra, MD; Elizabeth Zink, MAS; Matthew Fuller, PharmD; Brigid Wilson, PhD; Meera Kumari, MBBS; Kuldeep Vaghela, MD; Amal Rubai, MD; Trevor Shaver, PA; Rawad EL Ghouli, MD; George Jaskiw, MD; and Kingman Strohl, MD

**DOI Number:** <https://doi.org/10.4088/PCC.25m04074>

### **LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE**

1. **Supplementary Table 1. Summary Statistics by Visit**

### **DISCLAIMER**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

## Supplementary Material

**Supplementary Table 1. Summary Statistics by Visit**

Summary Statistics by Visit		
	Pretreatment	1–3 Months Follow-Up Visit
n	53	36
Withdrawals		17
Mean (SD)	20.38 (4.579)	8.86 (6.749)
<b>Insomnia Diagnosis</b>		
No clinically significant insomnia (0-7)	1	17
Subthreshold Insomnia (8-14)	5	10
Moderate Clinical Insomnia (15-21)	25	9
Severe Clinical Insomnia (22-28)	22	0